Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome.
The purpose of this study is to evaluate the progression free survival and safety of
irinotecan plus S1 versus S1 alone in the patients with previously treated advanced
esophageal cancer